Loading...

Kimia Farma (Persero)

BST:HQP
Snowflake Description

Moderate growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
HQP
BST
IDR18,995B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

PT Kimia Farma (Persero) Tbk produces and sells medicines, herbal medicines, iodine, salts, quinine and their derivative products, and vegetable oils in Indonesia, Asia, Europe, Australia, Africa, and New Zealand. The last earnings update was 20 days ago. More info.


Add to Portfolio Compare Print
  • Kimia Farma (Persero) has significant price volatility in the past 3 months.
HQP Share Price and Events
7 Day Returns
6.5%
BST:HQP
0%
DE Pharmaceuticals
-0%
DE Market
1 Year Returns
84.1%
BST:HQP
-30.3%
DE Pharmaceuticals
-11.5%
DE Market
HQP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Kimia Farma (Persero) (HQP) 6.5% 8.6% -13.7% 84.1% 192.9% 216.9%
DE Pharmaceuticals 0% -5.9% -11.6% -30.3% -21.4% 5%
DE Market -0% -3.3% 2.1% -11.5% 8.9% 8.1%
1 Year Return vs Industry and Market
  • HQP outperformed the Pharmaceuticals industry which returned -30.3% over the past year.
  • HQP outperformed the Market in Germany which returned -11.5% over the past year.
Price Volatility
HQP
Industry
5yr Volatility vs Market
Related Companies

HQP Value

 Is Kimia Farma (Persero) undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Kimia Farma (Persero) to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Kimia Farma (Persero).

BST:HQP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.7%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BST:HQP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.695 (1 + (1- 25%) (36.13%))
0.922
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.92
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.922 * 5.96%)
5.72%

Discounted Cash Flow Calculation for BST:HQP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Kimia Farma (Persero) is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

BST:HQP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (IDR, Millions) Source Present Value
Discounted (@ 5.72%)
2019 -609,000.00 Analyst x1 -576,045.35
2020 -278,000.00 Analyst x1 -248,727.36
2021 -251,000.00 Analyst x1 -212,418.28
2022 171,000.00 Analyst x1 136,884.30
2023 450,000.00 Analyst x1 340,729.27
2024 733,539.12 Est @ 63.01% 525,363.14
2025 1,057,576.26 Est @ 44.17% 716,452.49
2026 1,385,324.85 Est @ 30.99% 887,701.01
2027 1,686,796.16 Est @ 21.76% 1,022,391.14
2028 1,944,903.72 Est @ 15.3% 1,115,043.90
Present value of next 10 years cash flows IDR3,707,374.25
BST:HQP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= IDR1,944,903.72 × (1 + 0.23%) ÷ (5.72% – 0.23%)
IDR35,488,696.79
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= IDR35,488,696.79 ÷ (1 + 5.72%)10
IDR20,346,228.22
BST:HQP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= IDR3,707,374.25 + IDR20,346,228.22
IDR24,053,602.47
Equity Value per Share
(IDR)
= Total value / Shares Outstanding
= IDR24,053,602.47 / 5,554.00
IDR4330.86
BST:HQP Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BST:HQP represents 6.0E-5x of IDX:KAEF
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
6.0E-5x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (IDR) x Listing Adjustment Factor
= IDR 4,330.86 x 6.0E-5
€0.24
Value per share (EUR) From above. €0.24
Current discount Discount to share price of €0.19
= -1 x (€0.19 - €0.24) / €0.24
21%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Kimia Farma (Persero) is available for.
Intrinsic value
21%
Share price is €0.1933 vs Future cash flow value of €0.24478
Current Discount Checks
For Kimia Farma (Persero) to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Kimia Farma (Persero)'s share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Kimia Farma (Persero)'s share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Kimia Farma (Persero)'s earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Kimia Farma (Persero)'s earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:HQP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in IDR IDR71.90
IDX:KAEF Share Price ** IDX (2019-05-22) in IDR IDR3420
Germany Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 27.6x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 20.26x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Kimia Farma (Persero).

BST:HQP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= IDX:KAEF Share Price ÷ EPS (both in IDR)

= 3420 ÷ 71.90

47.57x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kimia Farma (Persero) is overvalued based on earnings compared to the DE Pharmaceuticals industry average.
  • Kimia Farma (Persero) is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Kimia Farma (Persero)'s expected growth come at a high price?
Raw Data
BST:HQP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 47.57x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
17.8%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.83x
Germany Market PEG Ratio Median Figure of 271 Publicly-Listed Companies 1.49x

*Line of best fit is calculated by linear regression .

BST:HQP PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 47.57x ÷ 17.8%

2.67x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kimia Farma (Persero) is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Kimia Farma (Persero)'s assets?
Raw Data
BST:HQP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in IDR IDR406.53
IDX:KAEF Share Price * IDX (2019-05-22) in IDR IDR3420
Germany Pharmaceuticals Industry PB Ratio Median Figure of 9 Publicly-Listed Pharmaceuticals Companies 2.27x
Germany Market PB Ratio Median Figure of 576 Publicly-Listed Companies 1.78x
BST:HQP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= IDX:KAEF Share Price ÷ Book Value per Share (both in IDR)

= 3420 ÷ 406.53

8.41x

* Primary Listing of Kimia Farma (Persero).

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kimia Farma (Persero) is overvalued based on assets compared to the DE Pharmaceuticals industry average.
X
Value checks
We assess Kimia Farma (Persero)'s value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Kimia Farma (Persero) has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

HQP Future Performance

 How is Kimia Farma (Persero) expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
17.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Kimia Farma (Persero) expected to grow at an attractive rate?
  • Kimia Farma (Persero)'s earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Kimia Farma (Persero)'s earnings growth is expected to exceed the Germany market average.
  • Kimia Farma (Persero)'s revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
BST:HQP Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:HQP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 17.8%
BST:HQP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 18.6%
Germany Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 17.8%
Germany Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 3.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:HQP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in IDR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:HQP Future Estimates Data
Date (Data in IDR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 13,036,000 1,283,000 661,000 1
2020-12-31 11,039,000 818,000 546,000 1
2019-12-31 9,186,000 717,000 474,000 1
BST:HQP Past Financials Data
Date (Data in IDR Millions) Revenue Cash Flow Net Income *
2019-03-31 7,778,754 -989,985 399,319
2018-12-31 7,454,115 258,255 415,896
2018-09-30 7,132,869 -558,918 360,108
2018-06-30 6,893,928 -224,759 353,711
2018-03-31 6,419,703 -67,157 334,804
2017-12-31 6,127,479 5,241 326,786
2017-09-30 6,145,736 88,320 285,555
2017-06-30 5,957,153 134,225 268,890
2017-03-31 5,870,811 176,519 254,615
2016-12-31 5,811,503 198,051 267,414
2016-09-30 5,353,790 116,310 271,671
2016-06-30 5,241,479 141,386 277,575

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Kimia Farma (Persero)'s earnings are expected to grow by 17.8% yearly, however this is not considered high growth (20% yearly).
  • Kimia Farma (Persero)'s revenue is expected to grow by 18.6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:HQP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Kimia Farma (Persero) Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:HQP Future Estimates Data
Date (Data in IDR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 118.90 118.90 118.90 1.00
2020-12-31 98.30 98.30 98.30 1.00
2019-12-31 85.30 85.30 85.30 1.00
BST:HQP Past Financials Data
Date (Data in IDR Millions) EPS *
2019-03-31 71.90
2018-12-31 74.88
2018-09-30 64.84
2018-06-30 63.69
2018-03-31 60.28
2017-12-31 58.84
2017-09-30 51.41
2017-06-30 48.41
2017-03-31 45.84
2016-12-31 48.15
2016-09-30 48.91
2016-06-30 49.98

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Kimia Farma (Persero) is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Kimia Farma (Persero)'s future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Kimia Farma (Persero) has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

HQP Past Performance

  How has Kimia Farma (Persero) performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Kimia Farma (Persero)'s growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Kimia Farma (Persero)'s year on year earnings growth rate has been positive over the past 5 years.
  • Kimia Farma (Persero)'s 1-year earnings growth exceeds its 5-year average (19.3% vs 10.4%)
  • Kimia Farma (Persero)'s earnings growth has not exceeded the DE Pharmaceuticals industry average in the past year (19.3% vs 25.7%).
Earnings and Revenue History
Kimia Farma (Persero)'s revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Kimia Farma (Persero) Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:HQP Past Revenue, Cash Flow and Net Income Data
Date (Data in IDR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 7,778,753.99 399,319.43 1,979,780.94 13,230.45
2018-12-31 7,454,114.74 415,895.78 1,853,030.90 18,069.43
2018-09-30 7,132,869.20 360,107.51 1,768,091.51 29,888.69
2018-06-30 6,893,927.98 353,710.98 1,687,919.31 38,589.13
2018-03-31 6,419,702.65 334,803.63 1,641,605.27 14,854.35
2017-12-31 6,127,479.37 326,786.25 1,555,146.19 8,714.45
2017-09-30 6,145,736.19 285,555.30 1,440,328.88 22,726.32
2017-06-30 5,957,153.39 268,889.85 1,353,364.03 25,173.68
2017-03-31 5,870,810.78 254,614.67 1,241,024.09 27,084.41
2016-12-31 5,811,502.66 267,414.09 1,218,149.74 29,148.83
2016-09-30 5,353,789.57 271,670.66 1,161,794.06 25,227.41
2016-06-30 5,241,478.90 277,575.29 1,151,559.57 19,603.51
2016-03-31 4,984,012.34 259,512.02 1,061,876.99 20,394.99
2015-12-31 4,860,371.48 261,426.27 1,032,486.88 19,134.44
2015-09-30 4,917,457.77 275,686.29 965,922.45 16,994.39
2015-06-30 4,730,426.92 262,798.05 916,848.18 18,425.19
2015-03-31 4,669,013.30 276,466.95 897,852.17 15,120.28
2014-12-31 4,521,024.38 255,930.62 875,033.40 15,270.17
2014-09-30 4,609,869.40 236,926.94 886,780.97 16,445.75
2014-06-30 4,506,515.16 242,356.49 896,791.88 17,200.16
2014-03-31 4,415,610.52 213,478.44 893,439.89 18,772.19
2013-12-31 4,348,073.99 214,549.15 896,286.68 17,253.99
2013-09-30 3,785,716.00 178,448.14 900,975.32 18,027.55
2013-06-30 3,891,523.36 167,016.19 881,482.88 17,655.98
2013-03-31 3,823,887.42 199,087.11 852,662.61 17,636.96
2012-12-31 3,734,241.10 205,133.32 832,412.35 14,785.72
2012-09-30 3,825,312.04 199,473.56 831,351.83 8,668.30
2012-06-30 3,655,175.62 215,689.72 816,882.13 5,207.61

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Kimia Farma (Persero) has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Kimia Farma (Persero) used its assets less efficiently than the DE Pharmaceuticals industry average last year based on Return on Assets.
  • Kimia Farma (Persero)'s use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Kimia Farma (Persero)'s performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Kimia Farma (Persero) has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

HQP Health

 How is Kimia Farma (Persero)'s financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Kimia Farma (Persero)'s finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Kimia Farma (Persero) is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Kimia Farma (Persero)'s cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Kimia Farma (Persero)'s finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Kimia Farma (Persero) Company Filings, last reported 1 month ago.

BST:HQP Past Debt and Equity Data
Date (Data in IDR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 2,708,845.59 6,863,566.67 1,099,559.01
2018-12-31 3,356,459.73 4,039,628.19 1,960,038.03
2018-09-30 2,784,132.73 4,174,300.75 1,363,622.62
2018-06-30 2,673,411.10 3,465,311.00 1,240,450.77
2018-03-31 2,609,105.31 2,460,099.08 699,885.36
2017-12-31 2,572,520.76 2,019,508.65 989,637.04
2017-09-30 2,424,738.97 1,894,047.80 626,028.54
2017-06-30 2,302,888.75 1,342,896.09 390,054.57
2017-03-31 2,293,877.88 1,054,715.48 432,574.52
2016-12-31 2,271,407.41 822,398.30 647,683.95
2016-09-30 2,334,362.84 874,352.80 367,591.77
2016-06-30 2,233,523.46 598,062.63 243,711.54
2016-03-31 2,233,672.36 502,521.44 340,082.86
2015-12-31 2,056,559.64 324,660.02 460,994.07
2015-09-30 1,797,457.65 404,124.14 162,436.44
2015-06-30 1,696,352.58 387,185.90 230,911.63
2015-03-31 1,856,401.79 264,456.38 350,691.37
2014-12-31 1,721,078.86 336,406.18 573,360.27
2014-09-30 1,714,145.35 311,782.09 154,598.53
2014-06-30 1,641,539.44 278,512.11 136,937.08
2014-03-31 1,594,559.65 56,859.43 262,642.71
2013-12-31 1,624,354.69 50,984.60 394,149.91
2013-09-30 1,530,658.35 143,964.23 170,041.63
2013-06-30 1,451,884.87 50,102.37 127,402.91
2013-03-31 1,466,070.94 18,153.16 192,905.99
2012-12-31 1,441,533.69 27,853.77 316,497.88
2012-09-30 1,384,407.50 85,090.76 147,538.00
2012-06-30 1,315,974.67 51,537.49 104,772.08
  • Kimia Farma (Persero)'s level of debt (253.4%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (3.7% vs 253.4% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Interest payments on debt are well covered by earnings (EBIT is 3.4x coverage).
X
Financial health checks
We assess Kimia Farma (Persero)'s financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Kimia Farma (Persero) has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

HQP Dividends

 What is Kimia Farma (Persero)'s current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Kimia Farma (Persero) dividends. Estimated to be 0.5% next year.
If you bought €2,000 of Kimia Farma (Persero) shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Kimia Farma (Persero)'s dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Kimia Farma (Persero)'s dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:HQP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Germany Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 3.2%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:HQP Future Dividends Estimate Data
Date (Data in IDR) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 19.70 1.00
2020-12-31 17.10 1.00
2019-12-31 15.00 1.00
BST:HQP Past Annualized Dividends Data
Date (Data in IDR) Dividend per share (annual) Avg. Yield (%)
2012-03-30 5.000 0.769
2011-03-01 5.000 1.981
2010-03-30 2.490 1.719
2009-06-05 2.490 1.811

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Kimia Farma (Persero) has not reported any payouts.
  • Unable to verify if Kimia Farma (Persero)'s dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Kimia Farma (Persero)'s earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Kimia Farma (Persero) has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Kimia Farma (Persero)'s dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Kimia Farma (Persero)'s dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Kimia Farma (Persero) afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Kimia Farma (Persero) has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

HQP Management

 What is the CEO of Kimia Farma (Persero)'s salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Honesti Basyir
AGE 50
TENURE AS CEO 2.1 years
CEO Bio

Mr. Honesti Basyir has been President Director at PT Kimia Farma (Persero) Tbk since April 20, 2017. He served as Director of Wholesale & International Service of Enterprise and Business Service at PT Telekomunikasi Indonesia Tbk from December 2014 to 2017 and has been and Acting Director since September 13, 2016 and served as its Corporate Secretary. He was Finance Director of PT Telkom Indonesia (Persero) Tbk from 2012 to 2014. Mr. Basyir served as Vice President of Investor Relations at PT Telekomunikasi Indonesia Tbk until March 4, 2015 and served as its Chief Financial Officer. Mr. Basyir has been Director of Finance at PT Telekomunikasi Indonesia Tbk since May 11, 2012. He served as Vice President Strategic Business Development in Strategic Investment and Corporate Planning Unit of PT Telkom Indonesia (Persero) Tbk from 2010 to 2012. Mr. Basyir served as a Vice President of Strategic Business Development at ITSS Directorate since 2012. He served as a Vice President of Strategic Business Development at SICP from 2010 to 2012; Project Controller-1 of Project Management Office from 2009 to 2010 and an Assistant Vice President of Business & Finance Analysis from 2006 to 2009. He had served as a Director at PT Telekomunikasi Indonesia Tbk since May 11, 2012 until April 20, 2017. He holds a Bachelor’s degree in Industrial Technology from Institut Teknologi Bandung (1992) and a Master’s degree in Corporate Finance from Sekolah Tinggi Manajemen Bandung (2004).

CEO Compensation
  • Insufficient data for Honesti to compare compensation growth.
  • Insufficient data for Honesti to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Kimia Farma (Persero) management team in years:

2.1
Average Tenure
50
Average Age
  • The tenure for the Kimia Farma (Persero) management team is about average.
Management Team

Honesti Basyir

TITLE
President Director
AGE
50
TENURE
2.1 yrs

I Gusti Ngurah Wijaya

TITLE
Finance Director & Director
AGE
51
TENURE
2.1 yrs

Fonny Yulina

TITLE
Head of Compliance & Risk Management Unit
AGE
51
TENURE
4.8 yrs

- Subandi

TITLE
General Affair & Human Capital Director and Director
TENURE
0.3 yrs

R. Ikhwani

TITLE
Head of Internal Control Unit
AGE
51
TENURE
4 yrs

Verdi Budidarmo

TITLE
Director of Production & Supply Chain and Director
AGE
49
TENURE
2.1 yrs

Andi Prazos

TITLE
Business Development Director & Director
AGE
49
TENURE
0.3 yrs

Ganti Putro

TITLE
General Manager of Corporate Secretary
AGE
39
TENURE
1.5 yrs
Board of Directors Tenure

Average tenure and age of the Kimia Farma (Persero) board of directors in years:

1.6
Average Tenure
50
Average Age
  • The average tenure for the Kimia Farma (Persero) board of directors is less than 3 years, this suggests a new board.
Board of Directors

Honesti Basyir

TITLE
President Director
AGE
50
TENURE
2.1 yrs

I Gusti Ngurah Wijaya

TITLE
Finance Director & Director
AGE
51
TENURE
2.1 yrs

- Subandi

TITLE
General Affair & Human Capital Director and Director
TENURE
0.3 yrs

Verdi Budidarmo

TITLE
Director of Production & Supply Chain and Director
AGE
49
TENURE
2.1 yrs

Andi Prazos

TITLE
Business Development Director & Director
AGE
49
TENURE
0.3 yrs

Wahono Sumaryono

TITLE
Independent Commissioner
AGE
64
TENURE
8.3 yrs

Untung Sutarjo

TITLE
President Commissioner
AGE
60
TENURE
1.1 yrs

- Nurrachman

TITLE
Independent Commissioner
AGE
50
TENURE
1.1 yrs

Muh Fauzi

TITLE
Commissioner
AGE
49
TENURE
3.1 yrs

Chrisma Albandjar

TITLE
Commissioner
AGE
45
TENURE
1.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Kimia Farma (Persero)'s management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Kimia Farma (Persero) has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

HQP News

Simply Wall St News

HQP Company Info

Description

PT Kimia Farma (Persero) Tbk produces and sells medicines, herbal medicines, iodine, salts, quinine and their derivative products, and vegetable oils in Indonesia, Asia, Europe, Australia, Africa, and New Zealand. It operates through Production, Distribution, Retail, and Others segments. It also provides hormones, narcotics, raw materials, contraceptives, OTC products, cosmetic and body care products, and food supplements. In addition, the company distributes medicines; and operates drug materials plants. It sells its products to pharmacies, hospitals, drugstores, and modern markets. As of December 31, 2018, the company had 1,190 outlets, including 283 jointly operated pharmacy outlets; and 905 owned pharmacy outlets, as well as 2 franchises in Indonesia. It operates 530 health clinics. The company was founded in 1817 and is headquartered in Jakarta, Indonesia.

Details
Name: PT Kimia Farma (Persero) Tbk
HQP
Exchange: BST
Founded: 1817
IDR1,173,685,885
5,554,000,000
Website: http://kimiafarma.co.id
Address: PT Kimia Farma (Persero) Tbk
Kantor Pusat,
Jalan Veteran No. 9,
Jakarta,
10110,
Indonesia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
IDX KAEF Series B Shares Indonesia Stock Exchange ID IDR 04. Jul 2001
BST HQP Series B Shares Boerse-Stuttgart DE EUR 04. Jul 2001
Number of employees
Current staff
Staff numbers
12,438
Kimia Farma (Persero) employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/23 00:21
End of day share price update: 2019/05/22 00:00
Last estimates confirmation: 2019/04/02
Last earnings filing: 2019/05/03
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.